{"title": "Blood single cell immune profiling reveals the interferon-MAPK pathway mediated adaptive immune response for COVID-19", "doi": "10.1101/2020.03.15.20033472", "citation_id": "2020.03.15.20033472v1", "date": "2020-03-17", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.15.20033472", "abstract": "<p>The coronavirus disease 2019 (COVID-19) outbreak is an ongoing global health emergence, but the pathogenesis remains unclear. We revealed blood cell immune response profiles using 59 mRNA, TCR and BCR V(D)J transcriptome analysis with single-cell resolution. Data from 134,620 PBMCs and 83,387 TCR and 12,601 BCR clones was obtained, and 56 blood cell subtypes and 23 new cell marker genes were identified from 16 participants. The number of specific subtypes of immune cells changed significantly when compared patients with controls. Activation of the interferon-MAPK pathway is the major defense mechanism, but MAPK transcription signaling is inhibited in cured patients. TCR and BCR V(D)J recombination is highly diverse in generating different antibodies against SARS-CoV-2. Therefore, the interferon-MAPK pathway and TCR- and BCR-produced antibodies play important roles in the COVID-19 immune response. Immune deficiency or immune over-response may result in the condition of patients with COVID-19 becoming critical or severe.</p>", "twitter_description": "The coronavirus disease 2019 (COVID-19) outbreak is an ongoing global health emergence, but the pathogenesis remains unclear. We revealed blood cell immune response profiles using 5' mRNA, TCR and BCR V(D)J transcriptome analysis with single-cell resolution. Data from 134,620 PBMCs and 83,387 TCR and 12,601 BCR clones was obtained, and 56 blood cell subtypes and 23 new cell marker genes were identified from 16 participants. The number of specific subtypes of immune cells changed significantly when compared patients with controls. Activation of the interferon-MAPK pathway is the major defense mechanism, but MAPK transcription signaling is inhibited in cured patients. TCR and BCR V(D)J recombination is highly diverse in generating different antibodies against SARS-CoV-2. Therefore, the interferon-MAPK pathway and TCR- and BCR-produced antibodies play important roles in the COVID-19 immune response. Immune deficiency or immune over-response may result in the condition of patients with COVID-19 becoming critical or severe.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis work was supported by the Sichuan Science and Technology Program (2020YFS0014 to Z.Y.), the Chinese Academy of Medical Sciences (No.2019-I2M-5-032), the National Key Research and Development Program of China (2016YFC20160905200), and the National Natural Science Foundation of China (81790643). \n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll sequencing data will be deposited in a public database and can be accessed online through a web portal.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20033472v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20033472v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.15.20033472v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/17/2020.03.15.20033472.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.15.20033472v1", "access_rights": "restricted", "authors": ["Lulin Huang", "Yi Shi", "Bo Gong", "Li Jiang", "Xiaoqi Liu", "Jialiang Yang", "Juan Tang", "Chunfang You", "Qi Jiang", "Bo Long", "Tao Zeng", "Mei Luo", "Fanwei Zeng", "Fanxin Zeng", "Shuqiang Wang", "Xingxiang Yang", "Zhenglin Yang"]}